Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 5, 2025
Event: Entry into a Material Definitive Agreement regarding the extension of a Rights Agreement.
Key Financial Metrics
This filing does not contain financial performance data. The document reports a corporate governance action rather than financial results. Consequently, no values are provided for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the execution of Amendment No. 5 to the Rights Agreement dated December 30, 2020, between Inmune Bio, Inc. and VStock Transfer, LLC. Key modifications include:
- Expiration Extension: The expiration date of the Rights Agreement has been extended to December 31, 2026.
- Automatic Renewal: The agreement now includes a provision for automatic extension for successive one-year terms unless the Board of Directors determines otherwise.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations or financial projections.
Risks and Contingencies: No specific risks or contingencies are detailed in this report beyond the standard incorporation of the full text of the Amendment by reference.
Investor Verification Checklist
- Verify the full text of Amendment No. 5 to the Rights Agreement (Exhibit 4.1) to understand specific terms of the poison pill or rights plan.
- Confirm the current status of the Rights Agreement and any prior amendments to assess the cumulative impact on shareholder rights.
- Review recent Board of Director meeting minutes or press releases for context on the decision to extend the agreement.